The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10969 malaria professionals are enjoying the free benefits of MalariaWorld today


Peptides of H. sapiens and P. falciparum that are predicted to bind strongly to HLA-A*24:02 and homologous to a SARS-CoV-2 peptide

June 23, 2021 - 13:35 -- Open Access
Adiguzel Y
Acta Trop. 2021 Jun 16:106013

This study is looking for a common pathogenicity between SARS-CoV-2 and Plasmodium species, in individuals with certain HLA serotypes.

SARS-CoV-2 and Plasmodium falciparum are probably adopting Analogous strategy to invade erythrocytes

June 15, 2021 - 15:14 -- Open Access
Konozy EHE, Osman MEM, Iesa MAM
J Infect Public Health. 2021 Jun 9;14(7):883-885

The highly contagious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which causes COVID-19 started at the end of 2019 in Wuhan city in China from where it stretched to the entire globe affecting different nations in different manners. Though this virus showed high potential to spread more quickly in certain territories within a short period of a few months.

Cross-reactivity of two SARS-CoV-2 serological assays in a malaria-endemic setting

April 20, 2021 - 15:12 -- Open Access
Steinhardt LC, Ige F, Audu R, et al.
J Clin Microbiol. 2021 Apr 14:JCM.00514-21

Accurate SARS-CoV-2 serological assays are critical for COVID-19 serosurveillance. However, previous studies have indicated possible cross-reactivity of these assays, including in malaria-endemic areas.

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants

March 17, 2021 - 16:51 -- Open Access
Nair MS, Huang Y, Fidock DA, Polyak SJ, Wagoner J, Towler MJ, Weathers PJ
J Ethnopharmacol. 2021 Mar 11:114016

Artemisia annua L. has been used for millennia in Southeast Asia to treat “fever”. Many infectious microbial and viral diseases have been shown to respond to A. annua and communities around the world use the plant as a medicinal tea, especially for treating malaria.

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

January 20, 2021 - 07:00 -- Open Access
Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M
PLoS Pathog. 2021 Jan 19;17(1):e1009212

Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This compound is known to interfere with endosomal acidification necessary to the proteolytic activity of cathepsins. Following receptor binding and endocytosis, cathepsin L can cleave the SARS-CoV-1 and SARS-CoV-2 spike (S) proteins, thereby activating membrane fusion for cell entry.

Not Open Access | Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M(pro), using molecular docking and dynamics simulation studies

January 7, 2021 - 10:07 -- NOT Open Access
Ahamad S, Kanipakam H, Birla S, Ali MS, Gupta D
Eur J Pharmacol. 2021 Jan 5;890:173664

Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Main protease (Mpro) is one of the vital drug targets amongst all the coronaviruses, as the protein is indispensable for virus replication. The study aimed to identify promising lead molecules against Mpro enzyme through virtual screening of Malaria Venture (MMV) Malaria Box (MB) comprising of 400 experimentally proven compounds.

Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare workers

December 30, 2020 - 13:39 -- Open Access
Mahajan NN, Gajbhiye R, Bahirat S, Lokhande PD, Mathe A, Rathi S, Warty N, Mahajan K, Srivastava V, Kuppusamy P, Mohite SC
J Med Virol. 2020 Dec 24

Healthcare workers (HCWs) are at higher risk of contracting SARS‐CoV‐2 infection. Information regarding co‐infection of SARS‐CoV‐2 with vector‐borne diseases (malaria and dengue) is crucial especially for the countries wherein malaria and dengue are endemic. The objective was to study the prevalence, demographic, clinical presentations among HCWs with COVID‐19 and to compare the viral clearance in HCWs with COVID‐19 and co‐infection of malaria and dengue.

Tutankhamun's Antimalarial Drug for Covid-19

November 4, 2020 - 10:28 -- Open Access
Sommer AP, Försterling HD, Sommer KE
Drug Res (Stuttg). 2020 Oct 30

Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. Current efforts to treat Covid-19 are based on this strategy. The first drugs used in patients infected with SARS-CoV-2 were antimalarial drugs. It is their mechanism of action, i. e., rise in endosomal pH, which recommends them against the new coronavirus.

Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models

October 27, 2020 - 15:46 -- Open Access
Rosenke K, Jarvis MA, Feldmann H, et al.
JCI Insight. 2020 Oct 22:143174

We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in two animal disease models.

Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation

September 15, 2020 - 14:26 -- Open Access
Gendrot M, Andreani J, Pradines B, et al.
Travel Med Infect Dis. 2020 Sep 8:101873

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs.


Subscribe to RSS - SARS-CoV-2